Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 10/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296935 | 0.88 | CA1 (0.44) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL20313908 | 0.88 | CA1 (0.44) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL18297068 | 0.87 | CA1 (0.43) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL18297069 | 0.87 | CTSK (0.45) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL18297052 | 0.84 | CTSK (0.44) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL6373993 | 0.82 | CYP1A2 (0.47) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL6842368 | 0.80 | CYP1A2 (0.50) | CA1CA2CA7CYP1A2CYP2C9 | |
| SCHEMBL13934941 | 0.80 | CA1 (0.67) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL13934324 | 0.80 | CA1 (0.67) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL23016026 | 0.79 | CA1 (0.56) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179248-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179248-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | CA1 598/4885CA2 2519/4885CA7 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.